Leading cell therapy companies for solid tumors

Iovance Biotherapeutics has achieved a historic milestone with the approval of lifileucel (Amtagvi), the first cell therapy for a solid tumor. This approval validates the viability of cell therapies in the treatment of advanced solid cancers.

Allogene Therapeutics is developing 'off-the-shelf' allogeneic CAR T therapies that have shown promising responses in metastatic solid tumors. Their AlloCAR T platform aims to overcome the limitations of autologous therapies, offering rapid availability and scalability.

Autolus Therapeutics is a leader in T-cell programming, with a portfolio of CAR T products under development for solid tumors. Their advanced technology aims to address both hematological malignancies and prostate cancers, among other solid tumors.

Inceptor Bio is advancing next-generation cell therapies for solid tumors, with its lead candidate IB-T101 in clinical trials. Its OUTLAST platform and focus on CAR-T, CAR-M, and CAR-NK demonstrate a commitment to innovation.

Arsenal Bio is developing programmed cell therapies with multiple coordinated synthetic pharmacologic functions for solid tumors. Bristol-Myers Squibb's exclusive license for its AB-4000 series validates its technology and accelerates the development of these therapies.

Bio4t2 is in the clinical phase with its candidate B4t2-001, utilizing an innovative platform to create genetically modified T cells. Its focus on recognizing overexpressed autoantigens in solid tumors positions it as a relevant company in the field.

AbbVie's collaboration with Calibr and Scripps Research on 'switchable' CAR-T therapies represents an innovative approach to improve safety and efficacy in solid tumors. This modular platform seeks to overcome challenges of specificity and toxicity.

Noile-Immune Biotech focuses on developing next-generation CAR-T cells designed to eradicate solid cancers. Its commitment to innovation in this field maintains its position as a key player in the search for effective solutions.

Immunocore, a leader in T-cell receptor (TCR) therapy, has initiated a Phase 3 study with tebentafusp for advanced melanoma. This advancement demonstrates the potential of TCR therapies to address complex solid tumors.

Immatics is developing adoptive cell therapies and bispecific TCRs to treat cancer, utilizing its XPRESIDENT platform to identify specific antigens. Its study for IMA203/IMA203CD8 in PRAME-positive solid tumors is an important step.

Affini-T Therapeutics focuses on T-cell therapies targeting oncogenic driver mutations like KRAS and p53 in solid tumors. Its TCR discovery platform and the use of synthetic biology position it as a promising company.

Lyell Immunopharma is advancing autologous TIL therapy with its candidate LYL845 for multiple solid tumors. Its work builds on the success of this modality in melanoma, seeking to expand its application to a variety of cancers.

Dragonfly Therapeutics develops Tri-specific NK cell Engager immunotherapies to activate natural killer (NK) cells and other innate immune cells. Its therapies are designed to counteract immunosuppression in the tumor microenvironment, crucial for solid tumors.

Fortress Biotech has developed CNDO-109, a compound that activates host immune system NK cells to destroy cancer cells. This NK-cell-based approach has broad potential for a variety of solid cancers.

Nkarta Therapeutics has developed proprietary technology to expand and engineer NK cells, enhancing their potency to eliminate cancer cells. Its focus on NKG2D and IL-15 expression is promising for solid tumors.

ImmunityBio is investigating its M-ceNK cells in Phase I for the treatment of solid tumors, demonstrating an active commitment to innovative therapies. Its enriched NK cells exhibit high cytotoxicity and a memory-like effect.

Dispatch Bio has received FDA authorization for its IND application for DISP-10, an innovative therapy for gastrointestinal cancers. Its Flare platform, which uses a tumor-specific virus, represents a significant advance for epithelial solid tumors.

Pan Cancer T is developing a next-generation TCR therapy targeting the ROPN1 antigen, designed to improve traction in difficult cancers such as triple-negative breast cancer. Its presentation at the CAR-TCR Summit Europe 2026 highlights its innovation.